source
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…BioSpace · 15d ago↗ source
- FDA extends review of Novo’s hemophilia A drug, citing manufacturing issuesDespite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.BioSpace · 15d ago↗ source
- Eli Lilly's Jaypirca receives FDA approval for first-line treatment of untreated CLL and SLLEli Lilly announced that the FDA has approved its drug Jaypirca as a first‑line therapy for patients with previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma. The appr…